Recombinant human epidermal growth factor: Difference between revisions
Added reference to Wagner Scale |
added Turkey as Country where Heberprot is in use (since 2014) |
||
| Line 8: | Line 8: | ||
==Clinical trials and use== |
==Clinical trials and use== |
||
The drug is currently in use in Cuba, Argentina, Colombia, Costa Rica, Ecuador, Guatemala, Mexico, Panamá <ref>[http://190.34.154.88/WFichasTecnicasApp/Operadores/FrmMedicamentos.aspx?Codigo=104331&ACCION=1&CodigoTabla=11%20&Eliminada=0 Panamá] Technical File in the Public Health Database </ref>, Paraguay, Peru, Uruguay, Venezuela, Russia and in the Domenican Republicand, Vietnam, and the Philippines. It has been submitted for patent examination in Canada.<ref>{{cite web|url=http://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2635013/summary.html?query=epidermal+growth+factor&start=1&num=50&type=basic_search |title=Canadian Patents Database, Patent Summary: USE OF A TOPICAL COMPOSITION CONTAINING EPIDERMAL GROWTH FACTOR (EGF) FOR DIABETIC FOOT AMPUTATION PREVENTION |publisher=Canadian Intellectual Property Office|date=2006-12-28 |accessdate=2012-09-08}}</ref> As of July 2012, China has started advanced stage-three tests of the drug, along with colleagues at 100 hospitals throughout the European Union.{{citation needed|date=December 2013}} These trials are the first time Cuban scientists have undertaken advanced clinical trials in developed countries.<ref>{{cite web|url=http://news.xinhuanet.com/english/china/2012-07/20/c_131727116.htm |title=China, Russia to test Cuban diabetes drug |publisher=Xinhua English |date=2012-07-20 |accessdate=2012-09-09}}</ref> |
The drug is currently in use in Cuba, Argentina, Colombia, Costa Rica, Ecuador, Guatemala, Mexico, Panamá <ref>[http://190.34.154.88/WFichasTecnicasApp/Operadores/FrmMedicamentos.aspx?Codigo=104331&ACCION=1&CodigoTabla=11%20&Eliminada=0 Panamá] Technical File in the Public Health Database </ref>, Paraguay, Peru, Uruguay, Venezuela, Russia, Turkey and in the Domenican Republicand, Vietnam, and the Philippines. It has been submitted for patent examination in Canada.<ref>{{cite web|url=http://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2635013/summary.html?query=epidermal+growth+factor&start=1&num=50&type=basic_search |title=Canadian Patents Database, Patent Summary: USE OF A TOPICAL COMPOSITION CONTAINING EPIDERMAL GROWTH FACTOR (EGF) FOR DIABETIC FOOT AMPUTATION PREVENTION |publisher=Canadian Intellectual Property Office|date=2006-12-28 |accessdate=2012-09-08}}</ref> As of July 2012, China has started advanced stage-three tests of the drug, along with colleagues at 100 hospitals throughout the European Union.{{citation needed|date=December 2013}} These trials are the first time Cuban scientists have undertaken advanced clinical trials in developed countries.<ref>{{cite web|url=http://news.xinhuanet.com/english/china/2012-07/20/c_131727116.htm |title=China, Russia to test Cuban diabetes drug |publisher=Xinhua English |date=2012-07-20 |accessdate=2012-09-09}}</ref> |
||
The drug has been available in Algeria since 2008, and has seen use in 31 hospitals in the country.{{citation needed|date=December 2013}} It was used on 314 patients, with a success rate of 90%.{{citation needed|date=December 2013}} A local firm has applied to manufacture the drug in Algeria.<ref>{{cite web|url=http://www.djazairess.com/fr/liberte/126479 |title=L'Heberprot-P sauve 196 malades en Algérie: Traitement contre l'ulcère du pied diabétique|publisher=DjaZairess.com in French|date=2009-12-09|accessdate=2014-06-18}}</ref>{{better source|date=December 2013}} |
The drug has been available in Algeria since 2008, and has seen use in 31 hospitals in the country.{{citation needed|date=December 2013}} It was used on 314 patients, with a success rate of 90%.{{citation needed|date=December 2013}} A local firm has applied to manufacture the drug in Algeria.<ref>{{cite web|url=http://www.djazairess.com/fr/liberte/126479 |title=L'Heberprot-P sauve 196 malades en Algérie: Traitement contre l'ulcère du pied diabétique|publisher=DjaZairess.com in French|date=2009-12-09|accessdate=2014-06-18}}</ref>{{better source|date=December 2013}} |
||
Revision as of 14:33, 19 October 2014
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Heberprot-P is a drug developed in Cuba as a cure for diabetic foot ulcer.[citation needed] The product contains epidermal growth factor (EGF) to be applied by intra-lesional injections directly in the wound site.[1][non-primary source needed] It has been found to "promote granulation and healing in advanced diabetic foot ulcers".[2] Heberprot-P is indicated for the treatment of poor prognosis of deep, extensive, and terminal DFU not responding to comprehensive and/or extensive conventional methods, particularly in grades 3, 4 & 5 of Wagner’s Classification[3] with average ulcer size bigger than 20 cm2, of both neuropathic and ischemic etiology with high risk amputation.
Clinical trials and use
The drug is currently in use in Cuba, Argentina, Colombia, Costa Rica, Ecuador, Guatemala, Mexico, Panamá [4], Paraguay, Peru, Uruguay, Venezuela, Russia, Turkey and in the Domenican Republicand, Vietnam, and the Philippines. It has been submitted for patent examination in Canada.[5] As of July 2012, China has started advanced stage-three tests of the drug, along with colleagues at 100 hospitals throughout the European Union.[citation needed] These trials are the first time Cuban scientists have undertaken advanced clinical trials in developed countries.[6]
The drug has been available in Algeria since 2008, and has seen use in 31 hospitals in the country.[citation needed] It was used on 314 patients, with a success rate of 90%.[citation needed] A local firm has applied to manufacture the drug in Algeria.[7][better source needed]
In South east Asian countries such as Vietnam and the Philippines, this innovative biotech drug for preventing lower extremities amputation due to severe diabetic foot ulcers is being used as an advanced wound care healing drug and may be accessed through wound care clinics or wound care specialists among hospitals.[neutrality is disputed][citation needed]
The drug and clinical trials have been looked over by scientists in the USA, calling the drug "very clever"[This quote needs a citation], but the political situation between Cuba and the USA may have some effect on the drug being formally evaluated in the USA.[8][neutrality is disputed]
References
- ^ "Prescription Information". Center for Genetic Engineering and Biotechnology, Ave. 31 e/ 158 y 190, Cubanacán, Playa La Habana, Cuba. 2010. Retrieved 2012-09-08.
- ^ "Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study". International Wound Journal. December 2009. pp. 432–443. doi:10.1111/j.1742-481X.2009.00641.x. Retrieved 2012-09-08.
- ^ http://clinical.diabetesjournals.org/content/27/2/52/T1.expansion.html
- ^ Panamá Technical File in the Public Health Database
- ^ "Canadian Patents Database, Patent Summary: USE OF A TOPICAL COMPOSITION CONTAINING EPIDERMAL GROWTH FACTOR (EGF) FOR DIABETIC FOOT AMPUTATION PREVENTION". Canadian Intellectual Property Office. 2006-12-28. Retrieved 2012-09-08.
- ^ "China, Russia to test Cuban diabetes drug". Xinhua English. 2012-07-20. Retrieved 2012-09-09.
- ^ "L'Heberprot-P sauve 196 malades en Algérie: Traitement contre l'ulcère du pied diabétique". DjaZairess.com in French. 2009-12-09. Retrieved 2014-06-18.
- ^ "Cubans developing therapy for diabetic ulcers Treatment said to save limbs; U.S. scientist hails research, urges more tests". MSNBC. 2006-11-01. Retrieved 2012-09-08.